Introduction
Epilepsy occurs in as much as 2% of the North American population and may be found in every community. Proper diagnosis and appropriate drug therapy may keep 75% of people with epilepsy symptom-free. Some of the other 25% may respond to an alternative form of therapy or have some symptoms relieved by specific drug therapy.
Convulsions are the result of a variety of causes, not all of which are epilepsy. In addition, not all epileptic seizures are convulsions. Thus, in the context of the analyses discussed here, the term antiepileptic agents is more appropriate than anticonvulsant.
There are several classifications of epilepsy. Use of a uniform classification allows a more nearly accurate evaluation of drug effects. Investigatorshave been able to show that certain antiepileptic agents are more or less useful in different clinical settings (1) . Modern antiepileptic agents can be divided into several groups. Which kind to use is a complex topic on which there is not universal agreement. Frequently, these agents are used together in various com binations.
Monitoring is desirable for several reasons: (a) patient compliance may be documented; (b) dosage may be adjusted to drug concentrations, the differences in absorption, netabolism, and excretion among patients making dosage adjustments difficult otherwise; (c) for several antiepileptic agents, clinical response has been demonstrated to be related to total circulating drug concentration; (ci) toxic concentrations, which have been identifiedfor most antiepileptic agents, may be avoided (2).
Principle
The antiepileptic agents primidone, phenobarbital, phenytoin, and carbamazepine are extracted into a chloroform! methanol solvent mixture.
An aliquot of the extract is evaporated, reconstituted with mobile phase, and injected.
Thedrugsare separated by reversed-phase "high-pressure" liquid chromatography and emerge in the order stated (Figure 1 ). The effluent is monitored at 195 nm and 254 nm. Quantification is by the peak-height ratio method. 
Materials and Methods

Specimen Collection and Handling
Reversed-phase column (pBondapak
C18;Waters Associates), 250 x 4.6 mm (i.d.).
Note: Evaluator L.A.B. reports that a Spherisorb ODS (10-zxn particle size) column may be substituted for the -Bondapak C18 column; the order of elution, the limits of linearity, and the recovery are the same.
Dual-pen recorder (Houston Instruments, Omrnscribe
Model B5217-1, available from Waters Associates).
Magnetic stirrer (Model
PC353; Corning
Medical,
Medfleld, MA 02502).
5.
Centrifuge (Dynac II, 2500 rpm; Clay Adams, Parsippany, NJ 07054). 9. Fume hood.
Timer.
Precision pipette tips (Lancer).
12. Vortex-type mixer.
Filter/de-gas apparatus (Waters Associates Solvent
Clarification Kit, cat. no. IEAXX15O4700). 14. Flexible laboratory film (Parafilm
M; American Can
Co., Greenwich, CT 06830). 15. Water bath at 55 #{176}C. Working standard (20 mgfL): Dilute 2 mL of stock standard with de-ionized water to a final volume of 100 mL in a volumetric flask. This is stable for six months at 4#{176}C. 3. Add 300 pL of working internal standard to the tube and vortex-mix for 15 s. (2) . The method presented here is intended to be easily transferable and flexible for meeting individual laboratory needs. The mobile phase may be adjusted to delay or accelerate the elution of individual drugs if appropriate. Some workers may degas the mobile phase components before blending; however, we noted no degradation of the mobile phase prepared and handled as described above. For the purpose of this presentation, we analyzed each specimen within 24 h. Our experience, however, is that these samples are stable for as long as three days at 4 to 6#{176}C, or seven days or more at -20 #{176}C. If analysis is to be delayed beyond 24 h, we recommend that the samples be frozen and that each laboratory document sample stability under their own conditions.
Add 2 mL of a chloroformimethanol
We decided not to use guard columns in this procedure. If such apparatus is introduced, the user must be alert to note changes, if any, in the performance of the method.
Run-to-run (different days) precision (CV) for the method described is: primmdone 7% (mean 12.4 mg/L, n = 31); phenobarbital 5% (32.3 mg/L, n = 27); phenytoin 7% (17.7 mg/L, n = 31); carbamazepmne 7% (8.1 mg/L, n = 30). This precision is within the performance limits required for medical management (8).
Analytical recovery (Table 1) was established by dissolving pure drug in a small amount of methanol and diluting to a final volume with drug-free serum. Each sample was analyzed three times and the results averaged.
The following drugs in the expected therapeutic ranges do not interfere: gentamicin, tobramycin, procainamide (and its metabolite N-acetylprocainamide), lidocaine, theophylline, valproic acid, and ethosuximide. Ethosuximide is substantially removed during the extraction step; any remaining in the sample would elute just before primidone.
For some antiepileptic agents, a metabolite(s) may have antiseizure activity, in which case the metabolite should be quantified in addition to or instead of the parent drug. Phenytoin and phenobarbital are measured as the parent drug. Primidone should be monitored by quantifying the parent drug and its major metabolite phenobarbital. Although the carbamazepine-10,11-epoxide is considered by some to be the proper analyte for monitoring carbamazepine therapy, this is not widely accepted, and we did not study it.
The goal of antiepileptic therapy is to create a consistent concentration of drug and (or) its active metabolite(s) sufilcient to prevent seizures but low enough to prevent undesired effects. Monitoring the concentrations of specific antiepileptic agents and (or) metabolites in blood assumes a stable relationship between concentrations in the circulating blood (total drug) and concentrations at active sites (free drug at receptor) (2). 9. Reconstitute the dry residue with 100 pL of mobile phase and vortex-mix for 60 s, until completely dissolved.
Note: Evaluators F.M.S. and R.D. found that these residues of serum-based controls and patients' samples, when reconstituted with 100 iL of mobile phase, consistently produced a turbid solution. They recommend the use of a column inlet filter (e.g., Rheodyne Model 7302 Column Inlet Filter) or precoluinn (e.g.,
Pelliguard LC-18, Supelco cat. no. 5-8232) to extend the life of the analytical column.
10. Inject 20 iL of the reconstituted sample.
11. To shut down the chromatographic system, pump 1. If a peak height is off-scale, the serum should be diluted with de-ionized water and the diluted sample carried through the extraction procedure. The result is multiplied by that dilution factor.
2. Linearity of response to concentration has been established within the following ranges (mg/L): primidone, 2-25; phenobarbital, 2-80; phenytoin, 1-40; carbamazepine,
1-
40.
3. Because the response of carbamazepine is greater at 254 nm than at 195 nm, it is preferable to report the 254-nm results for this drug. The response to primidone is very poor at 254 nm, so that the results at the two wavelengths will frequently not agree; report only the 195-nm results for primidone.
Plasma may be substituted if appropriate in-house
studies verify the interchangeabilityof the specimens.
Carbamazepine
Results and Discussion
The role of therapeutic monitoring in patient care is well established. As an evolving clinical laboratory service, however, many areas remain unclear. The resolution of problems with accuracy in therapeutic drug monitoring await the establishment of definitive and (or) reference methods. Interlaboratory precision for these assays is similar to that of other clinical laboratory activities (3-7) . The level of intralaboratory precision required and that being achieved have been documented (8).
"High-pressure" liquid chromatography methods for drug Not only is it common practice to use antiepileptic agents in combination, but also one drug may affect the metabolism of the other(s). It is therefore desirable to quantify several agents in each sample, even if only one has been requested.
For instance, phenobarbital
should be checked in each sample submitted for phenytoin determination, because these two are frequently used together and phenobarbital has a marked influence on phenytoin metabolism. Likewise, phenobarbital, the major active metabolite of primidone, must be quantified in each sample submitted for primidone determination. The methods used for quantifying antiepileptic agents include spectrophotometry, gas-liquid chromatography, enzyme immunoassays, radioiminunoassay, and "high-pressure" liquid chromatography.
The underlying difference
among these techniques is the way in which the drug of interest is separated for quantification. Spectrophotometric assays lack the sensitivity and specificity attainable by more recently introduced methods such as immunoassays and chromatographic techniques.
Gas-liquid chromatogra-
phy is used widely and has the advantage of simultaneous quantification of several agents with one injection; however, this technique at times requires that some derivative of an analyte be made and is limited by thermal instability of some drugs (e.g., carbamazepine). Enzyme immunoassay and radioimmunoassay are good techniques for quantifying drugs for which specific reagents are available. A separate analysis for each agent and (or) its metabolite(s) is usually required when using immunoassays. "High-pressure" liquid chromatography allows for simultaneous measurement of a mixture of analytes in one sample injection without the need for derivative formation or markedly high temperatures.
